AAPG
AAPGHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, AAPG focuses on Biotechnology services and products. Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company carries a $1.44B market cap, placing it firmly in the small-cap category. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Market Cap
$1.44B
Beta
0.66
P/E (TTM)
—
P/E (Fwd)
-23.86
EPS (TTM)
$-2.26
EPS (Fwd)
$-0.65
ROE
-236.6%
ROA
-28.0%
Cash
$1.90B
Total Debt
$2.09B
Free CF
-$956.5M
52W Change
-55.3%
Annual Financials
Cash vs Debt
Where AAPG stands vs its 150-day and 200-day moving averages
As of the October 5, 2026 close, AAPG finished 22.65% below its 150-day moving average ($19.87) and 28.18% below its 200-day moving average ($21.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AAPG overbought or oversold?
At the October 5, 2026 close, AAPG's RSI(14) was 40.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, AAPG has $1.90B in cash with $2.09B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$956.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -236.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $209.7M (2022) to $574.1M (2025), reflecting a 174% increase over the period.
With a beta below 0.7, AAPG typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AAPG.